{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-25-000157","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2025-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.691140+00:00","generated_at":"2026-05-17T23:26:40.618697+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neurocrine Biosciences Q2 2025: Revenue $687.5M up 16.5% YoY; valbenazine Phase 3 schizophrenia miss","bullets":["Total revenue $687.5M; INGREZZA $624.4M (+8% YoY), CRENESSITY $53.2M (launch year).","GAAP diluted EPS $1.06 (vs $0.63 Q2 2024); Non-GAAP diluted EPS $1.65 (vs $1.63).","INGREZZA 2025 net product sales guidance narrowed to $2.50-2.55B from $2.50-2.60B.","CRENESSITY: 664 new patient enrollment start forms in Q2; 76% reimbursement coverage for dispensed scripts.","Phase 3 study of valbenazine for adjunctive schizophrenia did not meet primary endpoint; safety consistent."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-25-000157","json":"https://secwatch.observer/filing/0000914475-25-000157.json","markdown":"https://secwatch.observer/filing/0000914475-25-000157.md","text":"https://secwatch.observer/filing/0000914475-25-000157.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000157/0000914475-25-000157-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000157/nbix-20250730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:26:40.618697+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}